サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1375859

心臓バイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント別予測、2023年～2030年

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, CK-MB, Myoglobin, BNP And NT-proBNP), By Application (Acute Coronary Syndrome, Myocardial Infarction), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 120 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
心臓バイオマーカーの市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年10月04日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心臓バイオマーカー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の心臓バイオマーカー市場規模は、2023年から2030年にかけて14.6%のCAGRで拡大し、2030年には478億8,000万米ドルに達する見込みです。

急性冠症候群（ACS）の有病率の増加は、バイオマーカー技術の進歩とともに、市場成長を促進すると予想されています。心疾患の早期診断と予後に関する意識の高まりは、市場をさらに牽引すると予想されます。

NCBIによると、米国では2021年に1,550万人以上が冠動脈性心疾患に罹患しています。胸痛は救急外来を受診する最も一般的な理由の一つです。心臓病は米国における主要な死因の一つであり、41秒に1人が心臓発作を起こしていると推定されています。心臓バイオマーカーはACS診断において重要な役割を果たし、より迅速な治療方針の決定を促進します。

急性冠症候群のリスク層別化と診断におけるバイオマーカーの採用が進んでいることが、需要を後押ししています。不健康なライフスタイルが急性冠症候群と心筋梗塞の有病率を高めています。PoC診断の採用が増加していることが、心臓マーカーの使用を容易にし、セグメント革新を促進しています。病院やPoC環境における心臓バイオマーカーの採用におけるパラダイムシフトは、心筋トロポニンIと心筋トロポニンTの感度に関連するアッセイにおける最近の開発に起因しています。

さらに、新規アッセイの利用可能性の増加は、今後数年間の市場成長を促進すると予想される主要な要因の1つです。これが、このセグメントにおける新規参入企業の動きを後押ししています。例えば、2021年5月、Shenzhen Mindray Bio-Medical Electronics社は、心臓バイオマーカーの販売に携わるHyTest社を6億6,100万米ドルで買収する計画を発表しました。原材料の自社生産は、原材料の安定供給を確保するため、企業にとって最重要分野となりつつあります。

心臓バイオマーカー市場レポートハイライト

  • 種類別では、トロポニンが心血管疾患の診断に多く使用されていることから、2022年に最大の売上シェアを占めました。
  • 用途別では、冠動脈疾患の有病率の増加、疾患の診断と治療におけるバイオマーカーの用途拡大により、急性冠症候群分野が予測期間中に有利な速度で成長すると予測されます。
  • 北米は、診断と予後のためのツールとして心臓バイオマーカーを容易に採用できる発達したヘルスケアシステムの存在により、2022年の世界市場を独占しました。
  • アジア太平洋地域は、予測期間中に大きな成長が見込まれています。これは、対象人口が広く、中国や日本などの国々で研究開発投資を行っている大手企業が存在することに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 心臓バイオマーカー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 心臓バイオマーカー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 心臓バイオマーカー：タイプ推定・動向分析

  • 心臓バイオマーカー市場：重要なポイント
  • 心臓バイオマーカー市場：動向と市場シェア分析、2022年および2030年
  • トロポニン
    • トロポニン市場推計・予測、2018年から2030年まで
  • CK-MB
    • CK-MB市場推計・予測、2018年から2030年まで
  • ミオグロビン
    • ミオグロビン市場推計・予測、2018年から2030年まで
  • BNPとNT-proBNP
    • BNPおよびNT-proBNP市場推計・予測、2018年から2030年まで
  • その他
    • その他の市場推計・予測、2018年から2030年まで

第5章 心臓バイオマーカー：応用推定・動向分析

  • 心臓バイオマーカー市場：重要なポイント
  • 心臓バイオマーカー市場：動向と市場シェア分析、2022年および2030年
  • 急性冠症候群
  • 心筋梗塞
  • うっ血性心不全
  • その他

第6章 心臓バイオマーカー：最終用途推定・動向分析

  • 心臓バイオマーカー市場：重要なポイント
  • 心臓バイオマーカー市場：動向と市場シェア分析、2022年および2030年
  • 臨床検査
    • 臨床検査市場推計・予測、2018年から2030年まで
  • ポイントオブケア検査
    • ポイントオブケア検査市場推計・予測、2018年から2030年まで

第7章 心臓バイオマーカー市場：地域推定・動向分析

  • 地域別の見通し
  • 地域別の心臓バイオマーカー市場：重要なポイント
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers GmbH
    • F. Hoffmann-La Roche Ltd.
    • Danaher
    • BIOMERIEUX
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd.
    • Creative Diagnostics
    • Life Diagnostics
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 5 North America cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 20 UK cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 23 France cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 France cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 45 Japan cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 46 Japan cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 48 China cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 49 China cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 51 India cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 52 India cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 54 Australia cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 55 Australia cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 57 Thailand cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 58 Thailand cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Korea cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 60 South Korea cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 61 South Korea cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 63 Latin America cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Brazil cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Mexico cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cardiac biomarkers: Market outlook
  • Fig. 8 Cardiac biomarkers: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Cardiac biomarkers market driver impact
  • Fig. 13 Cardiac biomarkers market restraint impact
  • Fig. 14 Cardiac biomarkers market strategic initiatives analysis
  • Fig. 15 Cardiac biomarkers market: Type movement analysis
  • Fig. 16 Cardiac biomarkers market: Type outlook and key takeaways
  • Fig. 17 Troponin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 CK-MB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Myoglobin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 BNP and NT-proBNP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiac biomarkers market: Application movement analysis
  • Fig. 23 Cardiac biomarkers market: Application outlook and key takeaways
  • Fig. 24 Acute coronary syndrome market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myocardial infarction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Congestive heart failure market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiac biomarkers market: End use movement analysis
  • Fig. 29 Cardiac biomarkers market: End use outlook and key takeaways
  • Fig. 30 Laboratory testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Point of care testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pain management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Vaccine delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiac biomarkers market: Regional movement analysis
  • Fig. 37 Global cardiac biomarkers market: Regional outlook and key takeaways
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-083-5

Cardiac Biomarkers Market Growth & Trends:

The global cardiac biomarkers market size is expected to reach USD 47.88 billion by 2030, expanding at a CAGR of 14.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the NCBI, in 2021, in the U.S., over 15.5 million people were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S. and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The improving adoption of biomarkers in risk stratification and diagnosis of the acute coronary syndrome is impelling the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin T.

Moreover, the rise in the availability of novel assays is one of the major drivers anticipated to boost market growth in the upcoming years. This is driving the movement of new players in the segment. For instance, in May 2021, Shenzhen Mindray Bio-Medical Electronics announced its plan to acquire HyTest, which is involved in cardiac biomarkers sales, for USD 661 million. In-house production of raw materials is becoming an area of prime focus for companies to ensure a steady flow of raw materials.

Cardiac Biomarkers Market Report Highlights:

  • By type, the troponin segment held the largest revenue share in 2022 owing to its high usage in cardiovascular diseases diagnosis
  • Based on application, the acute coronary syndrome segment is expected to grow at a lucrative rate during the forecast period due to the increasing prevalence of coronary diseases and expanding applications of these biomarkers in the diagnosis and treatment of diseases
  • North America dominated the global market in 2022 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
  • Asia Pacific is expected to grow at a significant rate during the forecast period. This can be attributed to the presence of a wide target population and leading companies that are making R&D investments in countries such as China and Japan

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Application
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cardiac Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Cardiac Biomarkers Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Cardiac Biomarkers: Type Estimates & Trend Analysis

  • 4.1. Cardiac Biomarkers Market: Key Takeaways
  • 4.2. Cardiac Biomarkers Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Troponin
    • 4.3.1. Troponin market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. CK-MB
    • 4.4.1. CK-MB market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Myoglobin
    • 4.5.1. Myoglobin market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. BNP and NT-proBNP
    • 4.6.1. BNP and NT-proBNP market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cardiac Biomarkers: Application Estimates & Trend Analysis

  • 5.1. Cardiac Biomarkers Market: Key Takeaways
  • 5.2. Cardiac Biomarkers Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Acute Coronary Syndrome
    • 5.3.1. Acute coronary syndrome market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Myocardial Infarction
    • 5.4.1. Myocardial infarction market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Congestive Heart Failure
    • 5.5.1. Congestive heart failure market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cardiac Biomarkers: End Use Estimates & Trend Analysis

  • 6.1. Cardiac Biomarkers Market: Key Takeaways
  • 6.2. Cardiac Biomarkers Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Laboratory Testing
    • 6.3.1. Laboratory testing market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Point of Care Testing
    • 6.4.1. Point of care testing market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cardiac Biomarkers Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Cardiac Biomarkers Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
    • 8.2.1. Abbott
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Quidel Corporation
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Siemens Healthineers GmbH
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. F. Hoffmann-La Roche Ltd.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Danaher
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. BIOMERIEUX
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Bio-Rad Laboratories, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Randox Laboratories Ltd.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Creative Diagnostics
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Life Diagnostics
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives